• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

mSphere . Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 20

tetano

Editor, Senior Moderator
mSphere


. 2022 May 19;e0084121.
doi: 10.1128/msphere.00841-21. Online ahead of print.
Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020


Cesar A Lopez[SUP] #[/SUP][SUP] 1 [/SUP], Clark H Cunningham[SUP] #[/SUP][SUP] 2 [/SUP], Sierra Pugh[SUP] 3 [/SUP], Katerina Brandt[SUP] 4 5 [/SUP], Usaphea P Vanna[SUP] 1 [/SUP], Matthew J Delacruz[SUP] 1 [/SUP], Quique Guerra[SUP] 1 [/SUP], D Ryan Bhowmik[SUP] 1 [/SUP], Samuel J Goldstein[SUP] 6 [/SUP], Yixuan J Hou[SUP] 7 [/SUP], Margaret Gearhart[SUP] 8 [/SUP], Christine Wiethorn[SUP] 9 [/SUP], Candace Pope[SUP] 9 [/SUP], Carolyn Amditis[SUP] 10 [/SUP], Kathryn Pruitt[SUP] 11 [/SUP], Cinthia Newberry-Dillon[SUP] 11 [/SUP], John L Schmitz[SUP] 12 [/SUP], Lakshmanane Premkumar[SUP] 1 [/SUP], Adaora A Adimora[SUP] 7 13 [/SUP], Ralph S Baric[SUP] 1 7 [/SUP], Michael Emch[SUP] 4 5 7 [/SUP], Ross M Boyce[SUP] 7 13 [/SUP], Allison E Aiello[SUP] 7 [/SUP], Bailey K Fosdick[SUP] 3 [/SUP], Daniel B Larremore[SUP] 14 15 [/SUP], Aravinda M de Silva[SUP] 1 [/SUP], Jonathan J Juliano[SUP] 7 13 [/SUP], Alena J Markmann[SUP] 13 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of deaths around the world within the past 2 years. Transmission within the United States has been heterogeneously distributed by geography and social factors with little data from North Carolina. Here, we describe results from a weekly cross-sectional study of 12,471 unique hospital remnant samples from 19 April to 26 December 2020 collected by four clinical sites within the University of North Carolina Health system, with a majority of samples from urban, outpatient populations in central North Carolina. We employed a Bayesian inference model to calculate SARS-CoV-2 spike protein immunoglobulin prevalence estimates and conditional odds ratios for seropositivity. Furthermore, we analyzed a subset of these seropositive samples for neutralizing antibodies. We observed an increase in seroprevalence from 2.9 (95% confidence interval [CI], 1.8 to 4.5) to 12.8 (95% CI, 10.6 to 15.2) over the course of the study. Latinx individuals had the highest odds ratio of SARS-CoV-2 exposure at 6.56 (95% CI, 4.66 to 9.44). Our findings aid in quantifying the degree of asymmetric SARS-CoV-2 exposure by ethnoracial grouping. We also find that 49% of a subset of seropositive individuals had detectable neutralizing antibodies, which was skewed toward those with recent respiratory infection symptoms. IMPORTANCE PCR-confirmed SARS-CoV-2 cases underestimate true prevalence. Few robust community-level SARS-CoV-2 ethnoracial and overall prevalence estimates have been published for North Carolina in 2020. Mortality has been concentrated among ethnoracial minorities and may result from a high likelihood of SARS-CoV-2 exposure, which we observe was particularly high among Latinx individuals in North Carolina. Additionally, neutralizing antibody titers are a known correlate of protection. Our observation that development of SARS-CoV-2 neutralizing antibodies may be inconsistent and dependent on severity of symptoms makes vaccination a high priority despite prior exposure.

Keywords: COVID-19; SARS-CoV-2; health disparities; neutralization; seroprevalence.
 
Back
Top Bottom